{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:30:03Z","timestamp":1777519803907,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20171181"],"award-info":[{"award-number":["BK20171181"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Key Research and Development Project of Social Development","award":["BE2019638"],"award-info":[{"award-number":["BE2019638"]}]},{"name":"Young Medical Talents of Jiangsu Science and Education Health Project","award":["QNRC2016791"],"award-info":[{"award-number":["QNRC2016791"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05852-3","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T03:46:41Z","timestamp":1718682401000},"page":"3033-3042","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinicopathological analysis of immunohistochemical CD47 and signal-regulatory protein-\u03b1 expression in Extranodal Natural killer\/T-cell lymphoma"],"prefix":"10.1007","volume":"103","author":[{"given":"Zaixiang","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1170-7074","authenticated-orcid":false,"given":"Wei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"issue":"10091","key":"5852_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F (2017) Non-hodgkin lymphoma. Lancet 390(10091):298\u2013310","journal-title":"Lancet"},{"key":"5852_CR2","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124\u20134130","journal-title":"J Clin Oncol"},{"issue":"11","key":"5852_CR3","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1","volume":"76","author":"M Yamaguchi","year":"1995","unstructured":"Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, Shirakawa S, Fukumoto M (1995) Frequent expression of P-glycoprotein\/MDR1 by nasal T\u2010cell lymphoma cells. Cancer 76(11):2351\u20132356","journal-title":"Cancer"},{"issue":"5","key":"5852_CR4","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","volume":"99","author":"M Yamaguchi","year":"2008","unstructured":"Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K (2008) Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced\u2010stage, relapsed or refractory extranodal natural killer (NK)\/T\u2010cell lymphoma and leukemia. Cancer Sci 99(5):1016\u20131020","journal-title":"Cancer Sci"},{"issue":"1","key":"5852_CR5","doi-asserted-by":"publisher","first-page":"7118","DOI":"10.1038\/s41598-022-11247-z","volume":"12","author":"GN Wang","year":"2022","unstructured":"Wang GN, Zhao WG, Zhang X-D, Jian X-Y, Zhang C-L, Zhang M-Z, Li WC (2022) A retrospective study on the clinicopathological and molecular features of 22 cases of natural killer\/T-cell lymphoma in children and adolescents. Sci Rep 12(1):7118","journal-title":"Sci Rep"},{"key":"5852_CR6","doi-asserted-by":"crossref","unstructured":"Shen Z, Wang Y, Xie R, Zhang Q, Xing X, Zhang S, Liu H, Sang W (2024) Clinicopathologic features and survival outcomes of CD30 expression in extranodal natural killer\/T-cell lymphoma. American journal of clinical pathology:aqae012","DOI":"10.1093\/ajcp\/aqae012"},{"issue":"6","key":"5852_CR7","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/cam4.3768","volume":"10","author":"X Wang","year":"2021","unstructured":"Wang X, Wang Y, Hu J, Xu H (2021) An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity. Cancer Med 10(6):2125\u20132136","journal-title":"Cancer Med"},{"issue":"1","key":"5852_CR8","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1038\/s41467-021-25475-w","volume":"12","author":"G Fenalti","year":"2021","unstructured":"Fenalti G, Villanueva N, Griffith M, Pagarigan B, Lakkaraju SK, Huang RY-C, Ladygina N, Sharma A, Mikolon D, Abbasian M (2021) Structure of the human marker of self 5-transmembrane receptor CD47. Nat Commun 12(1):5218","journal-title":"Nat Commun"},{"issue":"3","key":"5852_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","volume":"11","author":"EJ Brown","year":"2001","unstructured":"Brown EJ, Frazier WA (2001) Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11(3):130\u2013135","journal-title":"Trends Cell Biol"},{"key":"5852_CR10","first-page":"715","volume":"41","author":"L Cheng","year":"2012","unstructured":"Cheng L, Li Y, Zhang S, Teng X (2012) Molecular pathology of lung cancer: key to personalized medicine. Chin J Pathol 41:715\u2013720","journal-title":"Chin J Pathol"},{"issue":"5","key":"5852_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1083\/jcb.200708043","volume":"180","author":"RK Tsai","year":"2008","unstructured":"Tsai RK, Discher DE (2008) Inhibition of self engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 180(5):989\u20131003","journal-title":"J Cell Biol"},{"key":"5852_CR12","doi-asserted-by":"publisher","first-page":"757480","DOI":"10.3389\/fimmu.2022.757480","volume":"13","author":"Z Hai","year":"2022","unstructured":"Hai Z, Shucheng C, Junwei M, Hongwei X, Zhiyong Y (2022) CD47 as a promising therapeutic target in oncology. Front Immunol 13:757480","journal-title":"Front Immunol"},{"key":"5852_CR13","doi-asserted-by":"crossref","unstructured":"Hu H, Cheng R, Wang Y, Wang X, Wu J, Kong Y, Zhan S, Zhou Z, Zhu H, Yu R (2023) Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47. J Clin Investig 133 (2)","DOI":"10.1172\/JCI153470"},{"issue":"5","key":"5852_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1021\/acs.molpharmaceut.2c00073","volume":"19","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhao C, Liu Y, Wang C, Jiang H, Hu Y, Wu J (2022) Recent advances of tumor therapy based on the CD47-SIRP\u03b1 axis. Mol Pharm 19(5):1273\u20131293","journal-title":"Mol Pharm"},{"issue":"2","key":"5852_CR15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr., van Rooijen N, Weissman IL (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138(2):286\u2013299. https:\/\/doi.org\/10.1016\/j.cell.2009.05.045","journal-title":"Cell"},{"issue":"7","key":"5852_CR16","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1111\/cas.14437","volume":"111","author":"R Kazama","year":"2020","unstructured":"Kazama R, Miyoshi H, Takeuchi M, Miyawaki K, Nakashima K, Yoshida N, Kawamoto K, Yanagida E, Yamada K, Umeno T, Suzuki T, Kato K, Takizawa J, Seto M, Akashi K, Ohshima K (2020) Combination of CD47 and signal-regulatory protein-\u03b1 constituting the don\u2019t eat me signal is a prognostic factor in diffuse large B-cell lymphoma. Cancer Sci 111(7):2608\u20132619. https:\/\/doi.org\/10.1111\/cas.14437","journal-title":"Cancer Sci"},{"issue":"5","key":"5852_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-hodgkin lymphoma. Cell 142(5):699\u2013713. https:\/\/doi.org\/10.1016\/j.cell.2010.07.044","journal-title":"Cell"},{"issue":"5","key":"5852_CR18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/hon.2768","volume":"38","author":"E Yanagida","year":"2020","unstructured":"Yanagida E, Miyoshi H, Takeuchi M, Yoshida N, Nakashima K, Yamada K, Umeno T, Shimasaki Y, Furuta T, Seto M, Ohshima K (2020) Clinicopathological analysis of immunohistochemical expression of CD47 and SIRP\u03b1 in adult T-cell leukemia\/lymphoma. Hematol Oncol 38(5):680\u2013688. https:\/\/doi.org\/10.1002\/hon.2768","journal-title":"Hematol Oncol"},{"issue":"3","key":"5852_CR19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/bjc.2017.173","volume":"117","author":"L Barrera","year":"2017","unstructured":"Barrera L, Montes-Serv\u00edn E, Hernandez-Martinez J-M, Garc\u00eda-Vicente Mdl\u00c1, Montes-Serv\u00edn E, Herrera-Mart\u00ednez M, Crisp\u00edn JC, Borbolla-Escoboza JR, Arrieta O (2017) CD47 overexpression is associated with decreased neutrophil apoptosis\/phagocytosis and poor prognosis in non-small-cell lung cancer patients. Br J Cancer 117(3):385\u2013397. https:\/\/doi.org\/10.1038\/bjc.2017.173","journal-title":"Br J Cancer"},{"issue":"3","key":"5852_CR20","first-page":"151","volume":"9","author":"Y Chen","year":"2023","unstructured":"Chen Y, Klingen TA, Aas H, Wik E, Akslen LA (2023) CD47 and CD68 expression in breast cancer is associated with tumor-infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis. J Pathology: Clin Res 9(3):151\u2013164","journal-title":"J Pathology: Clin Res"},{"issue":"15","key":"5852_CR21","doi-asserted-by":"publisher","first-page":"11958","DOI":"10.3390\/ijms241511958","volume":"24","author":"JA Torres","year":"2023","unstructured":"Torres JA, Brito ABC, Silva VSe, Messias IM, Braun AC, Ruano APC, Buim ME, Carraro DM, Chinen LTD (2023) CD47 expression in circulating Tumor cells and circulating Tumor Microemboli from Non-small Cell Lung Cancer patients is a poor prognosis factor. Int J Mol Sci 24(15):11958","journal-title":"Int J Mol Sci"},{"issue":"7","key":"5852_CR22","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr., Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"11","key":"5852_CR23","first-page":"1229","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S (2022) The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood J Am Soc Hematol 140(11):1229\u20131253","journal-title":"Blood J Am Soc Hematol"},{"key":"5852_CR24","doi-asserted-by":"publisher","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance AL, Lymphoma G, Eastern Cooperative Oncology G, European Mantle Cell Lymphoma C, Italian Lymphoma F, European Organisation for R, Treatment of Cancer\/Dutch Hemato-Oncology G, Grupo Espanol de Medula O, German High-Grade Lymphoma Study G, German Hodgkin\u2019s Study G, Japanese Lymphorra Study G, Lymphoma Study A, Group NCT, Nordic Lymphoma Study, Southwest Oncology G, G, United Kingdom National Cancer Research I (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32 (27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","DOI":"10.1200\/JCO.2013.54.8800"},{"issue":"8","key":"5852_CR25","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1038\/s41375-020-0740-1","volume":"34","author":"H Hong","year":"2020","unstructured":"Hong H, Li Y, Lim ST, Liang C, Huang H, Yi P, Wu T, Du X, Zhang M, Wang J, Zhu J, Liu T, Meng F, Wu G, Guo Y, Zhu Y, Zhao W, Jin J, Li J, Deng Y, Gu K, Wu X, Ke X, Xie D, Lin D, Peng Z, Wu J, Liu Q, Kim WS, Lin T (2020) A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group. Leukemia 34(8):2243\u20132248. https:\/\/doi.org\/10.1038\/s41375-020-0740-1","journal-title":"Leukemia"},{"key":"5852_CR26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3389\/fonc.2019.00386","volume":"9","author":"Q Cai","year":"2019","unstructured":"Cai Q, Cai J, Fang Y, Young KH (2019) Epstein-Barr virus-positive natural killer\/T-cell lymphoma. Front Oncol 9:386","journal-title":"Front Oncol"},{"key":"5852_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/A:1015587423262","volume":"19","author":"C Brigati","year":"2002","unstructured":"Brigati C, Noonan DM, Albini A, Benelli R (2002) Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 19:247\u2013258","journal-title":"Clin Exp Metastasis"},{"key":"5852_CR28","doi-asserted-by":"crossref","unstructured":"Cioroianu AI, Stinga PI, Sticlaru L, Cioplea MD, Nichita L, Popp C, Staniceanu F (2019) Tumor microenvironment in diffuse large B-cell lymphoma: role and prognosis. Analytical Cellular Pathology 2019","DOI":"10.1155\/2019\/8586354"},{"issue":"2","key":"5852_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3324\/haematol.2014.113472","volume":"100","author":"S Riihij\u00e4rvi","year":"2015","unstructured":"Riihij\u00e4rvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, Karjalainen-Lindsberg M-L, Delabie J, Smeland E, Holte H (2015) Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a nordic phase II trial. Haematologica 100(2):238","journal-title":"Haematologica"},{"issue":"2","key":"5852_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/hon.2142","volume":"33","author":"F Marchesi","year":"2015","unstructured":"Marchesi F, Cirillo M, Bianchi A, Gately M, Olimpieri OM, Cerchiara E, Renzi D, Micera A, Balzamino BO, Bonini S (2015) High density of CD68+\/CD163\u2009+\u2009tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. Hematol Oncol 33(2):110\u2013112","journal-title":"Hematol Oncol"},{"issue":"11","key":"5852_CR31","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3109\/10428194.2013.879713","volume":"55","author":"SJ Nam","year":"2014","unstructured":"Nam SJ, Go H, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK (2014) An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 55(11):2466\u20132476","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"5852_CR32","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1084\/jem.20062611","volume":"204","author":"X-N Kong","year":"2007","unstructured":"Kong X-N, Yan H-X, Chen L, Dong L-W, Yang W, Liu Q, Yu L-X, Huang D-D, Liu S-Q, Liu H (2007) LPS-induced down-regulation of signal regulatory protein \u03b1 contributes to innate immune activation in macrophages. J Exp Med 204(11):2719\u20132731","journal-title":"J Exp Med"},{"issue":"1","key":"5852_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bcmd.2010.02.016","volume":"45","author":"RK Tsai","year":"2010","unstructured":"Tsai RK, Rodriguez PL, Discher DE (2010) Self inhibition of phagocytosis: the affinity of \u2018marker of self\u2019CD47 for SIRP\u03b1 dictates potency of inhibition but only at low expression levels. Blood Cells Molecules Dis 45(1):67\u201374","journal-title":"Blood Cells Molecules Dis"},{"issue":"42","key":"5852_CR34","doi-asserted-by":"publisher","first-page":"39833","DOI":"10.1074\/jbc.M203287200","volume":"277","author":"T Yamao","year":"2002","unstructured":"Yamao T, Noguchi T, Takeuchi O, Nishiyama U, Morita H, Hagiwara T, Akahori H, Kato T, Inagaki K, Okazawa H (2002) Negative regulation of platelet clearance and of the macrophage phagocytic response by the transmembrane glycoprotein SHPS-1. J Biol Chem 277(42):39833\u201339839","journal-title":"J Biol Chem"},{"key":"5852_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","volume":"32","author":"AN Barclay","year":"2014","unstructured":"Barclay AN, Van den Berg TK (2014) The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: structure, function, and therapeutic target. Annu Rev Immunol 32:25\u201350","journal-title":"Annu Rev Immunol"},{"issue":"49","key":"5852_CR36","doi-asserted-by":"publisher","first-page":"81305","DOI":"10.18632\/oncotarget.12874","volume":"7","author":"X Ye","year":"2016","unstructured":"Ye X, Zhang J, Lu R, Zhou G (2016) Signal regulatory protein \u03b1 associated with the progression of oral leukoplakia and oral squamous cell carcinoma regulates phenotype switch of macrophages. Oncotarget 7(49):81305","journal-title":"Oncotarget"},{"key":"5852_CR37","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1146\/annurev.immunol.23.021704.115742","volume":"26","author":"M Kronenberg","year":"2005","unstructured":"Kronenberg M (2005) Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 26:877\u2013900","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"5852_CR38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-hodgkin lymphoma. Cell 142(5):699\u2013713","journal-title":"Cell"},{"issue":"2","key":"5852_CR39","doi-asserted-by":"publisher","first-page":"e23081","DOI":"10.4161\/onci.23081","volume":"2","author":"JM Ho","year":"2013","unstructured":"Ho JM, Danska JS, Wang JC (2013) Targeting SIRP\u03b1 in cancer. Oncoimmunology 2(2):e23081","journal-title":"Oncoimmunology"},{"issue":"9","key":"5852_CR40","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/cam4.478","volume":"4","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Tsujimoto H, Matsumura K, Kinoshita M, Takahata R, Matsumoto Y, Hiraki S, Ono S, Seki S, Yamamoto J (2015) CD 47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med 4(9):1322\u20131333","journal-title":"Cancer Med"},{"issue":"16","key":"5852_CR41","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1158\/1078-0432.CCR-14-2520","volume":"21","author":"MN McCracken","year":"2015","unstructured":"McCracken MN, Cha AC, Weissman IL (2015) Molecular pathways: activating T cells after cancer cell phagocytosis from blockade of CD47 don\u2019t eat me signals. Clin Cancer Res 21(16):3597\u20133601","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5852_CR42","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.canlet.2015.02.036","volume":"360","author":"Z Xiao","year":"2015","unstructured":"Xiao Z, Chung H, Banan B, Manning PT, Ott KC, Lin S, Capoccia BJ, Subramanian V, Hiebsch RR, Upadhya GA (2015) Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett 360(2):302\u2013309","journal-title":"Cancer Lett"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05852-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:09:32Z","timestamp":1722060572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05852-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5852"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05852-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"was obtained from the Affiliated Hospital of Xuzhou Medical University and this study was conducted by the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients enrolled in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}